The epidemiology of nephrotoxicity associated with conventional amphotericin B therapy

Harbarth, Stephan Jürgen; Pestotnik, Stanley L.; Lloyd, James F.; Burke, John P.; Samore, Matthew H.

doi:10.1016/s0002-9343(01)00928-7

Cited by 151 publications

(118 citation statements)

References 23 publications

Supporting

Mentioning

106

Contrasting

Unclassified

Order By: Relevance

“…Nanoparticles formulations, for example, are recognized as foreign bodies by the immune system; they are engulfed by macrophages and later released, reducing systemic side effects (Harbarth et al, 2001). …”

Section: Challenges Of Antifungal Therapy With Amphotericin Bmentioning

confidence: 99%

Difficulties in antifungal therapy with amphotericin B and the continuous search for new formulations: A literature review

Voncik¹,

Fermino²,

Cardoso³

et al. 2016

Afr. J. Pharm. Pharmacol.

View full text Add to dashboard Cite

Despite advances in the research on new antifungal agents, Amphotericin B (AmB) is still considered as the antifungal of choice for treating most systemic mycoses due to its potency and broad-spectrum action. However, this drug has limited use because of its toxic effects on kidneys, liver and blood. The search for new and safe formulations of AmB is essential because of the emergence of antifungal resistance to other drugs and the increased number of immunosuppressed patients. Nanoparticles are a promising alternative towards achieving lower toxicity and improved pharmacokinetic properties. This study is a literature review of the use of AmB and the toxicity of formulations. Some of the current new formulations show some advantageous characteristics as compared to AmB. However, there is still need for a continued search for an effectively improved formulation.

show abstract

Section: Challenges Of Antifungal Therapy With Amphotericin Bmentioning

confidence: 99%

Difficulties in antifungal therapy with amphotericin B and the continuous search for new formulations: A literature review

Voncik¹,

Fermino²,

Cardoso³

et al. 2016

Afr. J. Pharm. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…for 4-6 weeks in the treatment of bone infections (41) and bisphosphonates as Risedronate at 5 mg per day orally at least for 6 months in case of osteoporosis (42). From the drug point, delivering large amounts of drugs to the body may display an increase in bioavailability but could result with exorbitant irrational quantities of drug getting eliminated from the body with potential increase in undesired serious side effects as nephrotoxicity and hepatotoxicity and escalated treatment cost, as with antimicrobials (43). In certain cases of drugs as growth factors, even a high dose of growth factors injected directly as an aqueous solution might struggle to maintain the desired biologic effects in vivo because of in vivo metabolism and enzymatic digestion resulting in short half-life of the drug in the body (28,44).…”

Section: Bone Drugs and Local Deliverymentioning

confidence: 99%

Organic–Inorganic Composites for Bone Drug Delivery

Soundrapandian

Datta

2009

AAPS PharmSciTech

View full text Add to dashboard Cite

Abstract. This review paper attempts to provide an overview in the fabrication and application of organic-inorganic based composites in the field of local drug delivery for bone. The concept of local drug delivery exists for a few decades. However, local drug delivery in bone and specially application of composites for delivery of drugs to bone is an area for potential research interest in the recent time. The advantages attained by an organic-inorganic composite when compared to its individual components include their ability to release drug, adopting to the natural environment and supporting local area until complete bone regeneration, which make them carriers of interest for local drug delivery for bone.

show abstract

“…Contrary to antibiotics, the antifungal armamentorium is essentialy limited to two classes, namely the polyenes and the azole derivatives. Their use for the treatment of invasive fungal infection is sometimes limited by their secondary effects such as the dose-dependent polyene nephrotoxicity [2], or as the azole hepatotoxicity [3]. The closeness of the azole target, the fungal lanosterol-14-a-demethylase, to human cytochrome P450 also resulted in many drug-interactions [4].…”

Section: Introductionmentioning

confidence: 99%

Synthesis of reduced xanthatin derivatives andin vitroevaluation of their antifungal activity

Pinel¹,

Landreau²,

Séraphin³

et al. 2005

Journal of Enzyme Inhibition and Medicinal Chemistry

View full text Add to dashboard Cite

show abstract

The epidemiology of nephrotoxicity associated with conventional amphotericin B therapy

Cited by 151 publications

References 23 publications

Difficulties in antifungal therapy with amphotericin B and the continuous search for new formulations: A literature review

Difficulties in antifungal therapy with amphotericin B and the continuous search for new formulations: A literature review

Organic–Inorganic Composites for Bone Drug Delivery

Synthesis of reduced xanthatin derivatives andin vitroevaluation of their antifungal activity

Contact Info

Product

Resources

About